By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Biogen Idec, Inc. (Massachusetts) 

14 Cambridge Center

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-679-2000 Fax: 617-679-2617

Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit

Key Statistics

Ownership: Public

Web Site: Biogen
Employees: 1700
Symbol: BIIB



NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan  (crohn's & MS)

Dyax Corp.  Antibody phage display

Company News
AGTC (AGTC) Announces Achievement Of XLRS Patient Enrollment Milestone In Biogen (BIIB) Collaboration 8/27/2015 6:57:23 AM
Applied Genetic Surges on $1 Billion+ Eye Deal With Biogen (BIIB) 8/20/2015 6:08:12 AM
Biogen (BIIB), The ALS Association And Columbia University Medical Center Collaborate To Drive Understanding Of Genetic Influence In ALS 8/18/2015 11:21:42 AM
Biogen (BIIB), the ALS Association and Columbia University Medical Center to Map ALS With Ice Bucket Cash 8/18/2015 6:09:33 AM
Biogen (BIIB) Release: Results From B-YOND Extension Study Reinforce Long-Term Clinical Profile Of ALPROLIX For The Treatment Of Hemophilia B 8/17/2015 10:57:27 AM
Sale of Biogen (BIIB)'s Kendall Square HQ Would be One of the Most Expensive Deals in Boston This Year 8/13/2015 6:58:19 AM
Biogen (BIIB) Release: Extension Study Data Supporting Long-Term Safety And Efficacy Of Eloctate/Elocta Published In Haemophilia 8/10/2015 9:40:23 AM
Biogen (BIIB) Sinks Some More After Doctors Fear More Brain Infections Will Occur in Patients Taking Drugs Like Tecfidera 8/7/2015 6:09:50 AM
Watch Out Gilead (GILD), Investors Feel Vertex (VRTX) May Be Biogen (BIIB)'s Good Fit 7/31/2015 5:56:10 AM
Four Boston Biotechs That Could Make M&A Moves This Year 7/30/2015 5:26:16 AM